Download PDF

1. Company Snapshot

1.a. Company Description

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals.The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.It has collaboration agreements with Celsee, Inc.


for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc.for development and markets a novel pathogen detection system.The company was formerly known as Zomedica Pharmaceuticals Corp.


and changed its name to Zomedica Corp.in October 2020.Zomedica Corp.


was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Show Full description

1.b. Last Insights on ZOM

Negative drivers behind Zomedica Corp.'s recent performance include the commencement of delisting proceedings by NYSE American, citing the company's low selling price and unsuitability for listing. This led to the company's shares being suspended from trading and subsequently transitioning to the OTCQB Venture Market under the ticker symbol "ZOMDF". Additionally, the company's relocation to a new headquarters, while aimed at improving efficiency and reducing costs, may have caused temporary disruptions to its operations. Furthermore, the recent earnings call transcript revealed weak operational and financial highlights for the fourth quarter and full year 2024, which may have contributed to the company's negative performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Zomedica Corp. (ZOMDF) Q3 2025 Earnings Call Transcript

Nov -22

Source: seekingalpha.com

Card image cap

Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review

Nov -11

Source: accessnewswire.com

Card image cap

Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential

Nov -06

Source: accessnewswire.com

Card image cap

Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth

Nov -04

Source: accessnewswire.com

Card image cap

Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union

Oct -14

Source: accessnewswire.com

Card image cap

Zomedica and UXR Announce Expanded Distribution Agreement in Canada

Sep -10

Source: accessnewswire.com

Card image cap

Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio

Sep -03

Source: accessnewswire.com

Card image cap

Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

Aug -19

Source: accessnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.52%)

6. Segments

Therapeutics

Expected Growth: 8.5%

Zomedica Corp.'s therapeutics segment growth is driven by increasing demand for pet health solutions, expansion into new markets, and strategic partnerships. The company's innovative pipeline, including TRUFORMA, a point-of-care diagnostic platform, and ZM-020, a novel therapeutic for osteoarthritis, are key contributors to this growth.

Diagnostics

Expected Growth: 9.12%

Zomedica Corp.'s diagnostics segment growth of 9.12% is driven by increasing demand for veterinary diagnostic products, expansion into new markets, and strategic partnerships. The company's innovative diagnostic solutions, such as TRUFORMA, are gaining traction, and its focus on point-of-care testing is resonating with veterinarians, contributing to the segment's rapid growth.

7. Detailed Products

TRUFORMA

A point-of-care diagnostic biosensor platform that provides accurate and timely diagnostic results for veterinarians and pet owners.

ZM-017

A transdermal gel that provides a novel, non-invasive, and pain-free delivery method for medications and vaccines in animals.

ZM-011

A novel, non-invasive, and pain-free diagnostic tool for detecting and monitoring diseases in animals, such as cancer and inflammatory diseases.

ZM-006

A novel, non-invasive, and pain-free diagnostic tool for detecting and monitoring diseases in animals, such as gastrointestinal diseases.

8. Zomedica Corp.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Zomedica Corp. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the veterinary industry.

Bargaining Power Of Customers

Zomedica Corp.'s customers, primarily veterinarians and pet owners, have limited bargaining power due to the company's specialized products and services.

Bargaining Power Of Suppliers

Zomedica Corp. relies on a few key suppliers for its products, giving them some bargaining power, but the company's strong relationships and diversified supply chain mitigate this risk.

Threat Of New Entrants

The veterinary industry is attractive to new entrants, and Zomedica Corp. faces a high threat of new competitors entering the market, potentially disrupting its business.

Intensity Of Rivalry

Zomedica Corp. operates in a competitive market, but its specialized products and services help to differentiate it from rivals, reducing the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.12%
Debt Cost 6.66%
Equity Weight 98.88%
Equity Cost 8.86%
WACC 8.83%
Leverage 1.14%

11. Quality Control: Zomedica Corp. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Embecta

A-Score: 5.5/10

Value: 8.2

Growth: 1.7

Quality: 6.2

Yield: 7.0

Momentum: 7.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Amphastar Pharmaceuticals

A-Score: 4.8/10

Value: 7.1

Growth: 8.8

Quality: 8.0

Yield: 0.0

Momentum: 0.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Dynavax

A-Score: 4.7/10

Value: 6.3

Growth: 5.8

Quality: 4.8

Yield: 0.0

Momentum: 5.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
PetIQ

A-Score: 3.5/10

Value: 3.6

Growth: 7.8

Quality: 3.1

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Zomedica

A-Score: 3.3/10

Value: 8.2

Growth: 5.9

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Ironwood Pharmaceuticals

A-Score: 3.2/10

Value: 8.3

Growth: 4.2

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.1$

Current Price

0.1$

Potential

-0.00%

Expected Cash-Flows